Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Lennart Tonneijck; Mark M. Smits; Marcel H. A. Muskiet; Trynke Hoekstra; Mark H. H. Kramer; A. H. Jan Danser; Michaela Diamant; Jaap A. Joles; Daniël H. van Raalte

doi:10.1007/s00125-016-3938-z

Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

Diabetologia ◽

10.1007/s00125-016-3938-z ◽

2016 ◽

Vol 59 (7) ◽

pp. 1412-1421 ◽

Cited By ~ 55

Author(s):

Lennart Tonneijck ◽

Mark M. Smits ◽

Marcel H. A. Muskiet ◽

Trynke Hoekstra ◽

Mark H. H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Renal Effects ◽

Double Blind Placebo ◽

Diabetes Patients

Download Full-text

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050

Diabetes Care ◽

10.2337/dc19-er03 ◽

2019 ◽

Vol 42 (3) ◽

pp. 494.1-494 ◽

Cited By ~ 1

Author(s):

Lennart Tonneijck ◽

Mark M. Smits ◽

Marcel H.A. Muskiet ◽

Trynke Hoekstra ◽

Mark H.H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diabetes Care ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Renal Effects ◽

Double Blind Placebo

Download Full-text

Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Diabetes Care ◽

10.2337/dc16-1371 ◽

2016 ◽

Vol 39 (11) ◽

pp. 2042-2050 ◽

Cited By ~ 50

Author(s):

Lennart Tonneijck ◽

Mark M. Smits ◽

Marcel H.A. Muskiet ◽

Trynke Hoekstra ◽

Mark H.H. Kramer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Renal Effects ◽

Double Blind Placebo

Download Full-text

Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial

Diabetic Medicine ◽

10.1111/j.1464-5491.2010.03020.x ◽

2010 ◽

Vol 27 (9) ◽

pp. 1024-1032 ◽

Cited By ~ 108

Author(s):

R. E. Ratner ◽

J. Rosenstock ◽

G. Boka ◽

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Dose Dependent

Download Full-text

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

Diabetes Obesity and Metabolism ◽

10.1111/dom.12382 ◽

2014 ◽

Vol 16 (12) ◽

pp. 1257-1264 ◽

Cited By ~ 62

Author(s):

J. Reusch ◽

M. W. Stewart ◽

C. M. Perkins ◽

D. T. Cirkel ◽

J. Ye ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Randomized, double‐blind, placebo‐controlled trial of the once‐daily GLP ‐1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea ( GetGoal ‐L‐Asia)

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2012.01618.x ◽

2012 ◽

Vol 14 (10) ◽

pp. 910-917 ◽

Cited By ~ 188

Author(s):

Y. Seino ◽

K. W. Min ◽

E. Niemoeller ◽

A. Takami ◽

Keyword(s):

Type 2 Diabetes ◽

Basal Insulin ◽

Receptor Agonist ◽

Controlled Trial ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo ◽

Asian Patients

Download Full-text

Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

Diabetes Care ◽

10.2337/dc11-1935 ◽

2012 ◽

Vol 35 (6) ◽

pp. 1225-1231 ◽

Cited By ~ 154

Author(s):

V. A. Fonseca ◽

R. Alvarado-Ruiz ◽

D. Raccah ◽

G. Boka ◽

P. Miossec ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Once Daily ◽

Double Blind Placebo

Download Full-text

Metabolic improvement with short‐term glucagon like peptide‐1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double‐blind placebo‐controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14480 ◽

2021 ◽

Author(s):

Annemie Stege Bojer ◽

Martin Heyn Sørensen ◽

Jenny Bjerre ◽

Peter Gæde ◽

Niels Vejlstrup ◽

...

Keyword(s):

Type 2 Diabetes ◽

Diastolic Dysfunction ◽

Receptor Agonist ◽

Controlled Trial ◽

Short Term ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Faculty Opinions recommendation of Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735542506.793559665 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

Using ginger supplement in adjunct with non-surgical periodontal therapy improves metabolic and periodontal parameters in patients with type 2 diabetes mellitus and chronic periodontitis: A double-blind, placebo-controlled trial

Journal of Herbal Medicine ◽

10.1016/j.hermed.2019.100315 ◽

2020 ◽

Vol 20 ◽

pp. 100315

Author(s):

Hasan Gholinezhad ◽

Hadi Bazyar ◽

Homeira Rashidi ◽

Parvin Salehi ◽

Mohammad Hosein Haghighi-zadeh ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Chronic Periodontitis ◽

Controlled Trial ◽

Periodontal Therapy ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study)

BMJ ◽

10.1136/bmj.328.7441.686-b ◽

2004 ◽

Vol 328 (7441) ◽

pp. 686.3

Keyword(s):

Type 2 Diabetes ◽

Low Dose ◽

Controlled Trial ◽

Urinary Albumin ◽

Double Blind ◽

Double Blind Placebo ◽

Renal Outcomes

Download Full-text